- TWD11.84bn
- TWD12.82bn
- TWD1.79bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.16 | ||
| Price to Tang. Book | 2.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.39% | ||
| Return on Equity | -11.03% | ||
| Operating Margin | -40.49% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 1,299.69 | 1,869.15 | 1,793.78 | 2,251.62 | 1,785.09 | 2,860 | n/a | 16.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -96.35 | +516.03 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.
Directors
- Chi-Shean Chan CHM
- Chin-Chuan Chang COO
- Chung-Cheng Liu GMG
- Jin-Yi Chiou DGM
- Fei Pan OTH
- Yin-Teng Chang OTH
- Chun-Cheng Chen OTH
- Chien-Fu Chen DRC
- Wei-Kuang Chi DRC
- Chi-Heng Lin DRC
- Ching-Che Lin DRC
- Jung-Chin Lin DRC
- Mei-Hsing Tseng DRC
- Mei-Hsiang He IND
- Hsiao-Po Hsu IND
- Yung-Sheng Hsu IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 22nd, 1965
- Public Since
- September 29th, 2010
- No. of Employees
- 564
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Taiwan Stock Exchange- Shares in Issue
- 421,508,000
- Address
- No.3, TAICHUNG, 427
- Web
- https://www.adimmune.com.tw/
- Phone
- +886 425381220
- Contact
- Fei Pan
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 4142
Q2 2024 Adimmune Corp Earnings Release
Similar to 4142
Bora Pharmaceuticals Co
Taiwan Stock Exchange
China Chemical & Pharmaceutical Co
Taiwan Stock Exchange
Chunghwa Chemical Synthesis & Biotech Co
Taiwan Stock Exchange
Formosa Laboratories
Taiwan Stock Exchange
Lotus Pharmaceutical Co
Taiwan Stock Exchange
FAQ
What is the Adimmune share price?
As of Today at 19:00 UTC, shares in Adimmune are trading at TWD28.10. This share price information is delayed by 15 minutes.
How has the Adimmune share price performed this year?
Shares in Adimmune last closed at TWD28.10 and the price had moved by -25.17% over the past 365 days. In terms of relative price strength the Adimmune share price has underperformed the FTSE Developed Asia Pacific Index by -27.31% over the past year.
What are the analyst and broker recommendations for Adimmune?
The overall consensus recommendation for Adimmune is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Adimmune dividend yield?
Adimmune does not currently pay a dividend.
Does Adimmune pay a dividend?
Adimmune does not currently pay a dividend.
When does Adimmune next pay dividends?
Adimmune does not currently pay a dividend.
How do I buy Adimmune shares?
To buy shares in Adimmune you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adimmune?
As of the previous close price of TWD28.10, shares in Adimmune had a market capitalisation of TWD11.84bn.
Where are Adimmune shares listed?
Here are the trading details for Adimmune:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 4142
What kind of share is Adimmune?
Based on an overall assessment of its quality, value and momentum Adimmune is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adimmune share price forecast for 2024?
The analyst consensus target price for shares in Adimmune is TWD35.00. That is 24.56% above the last closing price of TWD28.10.
Analysts covering Adimmune currently have a consensus Earnings Per Share (EPS) forecast of TWD3.38 for the next financial year.
What is the trend in the Adimmune share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adimmune. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -21.49%.
As of the last closing price of TWD28.10, shares in Adimmune were trading -11.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adimmune PE Ratio?
The Adimmune PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD28.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adimmune?
Adimmune's management team is headed by:
- Chi-Shean Chan - CHM
- Chin-Chuan Chang - COO
- Chung-Cheng Liu - GMG
- Jin-Yi Chiou - DGM
- Fei Pan - OTH
- Yin-Teng Chang - OTH
- Chun-Cheng Chen - OTH
- Chien-Fu Chen - DRC
- Wei-Kuang Chi - DRC
- Chi-Heng Lin - DRC
- Ching-Che Lin - DRC
- Jung-Chin Lin - DRC
- Mei-Hsing Tseng - DRC
- Mei-Hsiang He - IND
- Hsiao-Po Hsu - IND
- Yung-Sheng Hsu - IND